NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Primary endpoint will be readily met statistically significantly, so will at least some secondary endpoints if not all.

DCVax-L for GBM alone would grantee a share price in the range from $10-$30.

And it's just a fraction of the platform technology DCVax consisting of DCVax-L for all solid operable tumors and DCVax-D for all solid inoperable tumors.

Use a calculator and your brain to calculate whatever way you like, the numbers of potential share price is staggering, any numbers from $30 up is achievable.

Based on what we all know, DCVax-L trial for GBM is a success, which validates the MOA or the concept of DCVax platform.

All others are just FUDs.